PLUS Therapeutics (PSTV) CEO receives large RSU and stock option grants

Rhea-AI Filing Summary

HEDRICK MARC H reported acquisition or exercise transactions in this Form 4 filing.

PLUS Therapeutics reported that Chief Executive Officer Marc H. Hedrick received new equity awards. He was granted 2,419,582 Restricted Stock Units, each representing one share of common stock, and 2,419,582 stock options with a right to buy common shares.

The RSUs vest in twelve equal quarterly installments, starting with the first 1/12th on April 1, 2026 and continuing quarterly thereafter. The stock options vest in 48 equal monthly installments over four years, and also vest upon a change of control as provided in his employment agreement.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider HEDRICK MARC H

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	2,419,582	$0.00	--
Grant/Award	Stock Option (Right to Buy)	2,419,582	$0.00	--

Holdings After Transaction: Restricted Stock Units — 4,016,388 shares (Direct); Stock Option (Right to Buy) — 2,419,582 shares (Direct)

Footnotes (1)

1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs awarded vest ratably over twelve quarters in substantially equal 1/12th increments, commencing with 1/12th vesting on April 1, 2026 and the remainder vesting quarterly thereafter. The options vest over four years in substantially equal 1/48th increments on each monthly anniversary of the issuance and vest on a change of control in accordance with the Optionee's employment agreement.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HEDRICK MARC H

(Last) (First) (Middle)

C/O PLUS THERAPEUTICS INC.

6420 LEVIT GREEN BOULEVARD, SUITE 310

(Street)

HOUSTON TX 77021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PLUS THERAPEUTICS, INC. [ PSTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/25/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0(1)	02/25/2026		A		2,419,582		(1)	(1)	Common Stock	2,419,582	$0	4,016,388	D
Stock Option (Right to Buy)	$0.28	02/25/2026		A		2,419,582		(2)	02/24/2036	Common Stock	2,419,582	$0	2,419,582	D

Explanation of Responses:

1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs awarded vest ratably over twelve quarters in substantially equal 1/12th increments, commencing with 1/12th vesting on April 1, 2026 and the remainder vesting quarterly thereafter.

2. The options vest over four years in substantially equal 1/48th increments on each monthly anniversary of the issuance and vest on a change of control in accordance with the Optionee's employment agreement.

	Andrew Sims, as attorney-in-fact	02/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did PSTV report for CEO Marc H. Hedrick?

PLUS Therapeutics reported that CEO Marc H. Hedrick received equity awards, not an open-market trade. He was granted 2,419,582 Restricted Stock Units and 2,419,582 stock options as part of his compensation, subject to multi-year vesting schedules and change-of-control terms.

How many Restricted Stock Units did the PSTV CEO receive in this Form 4?

Marc H. Hedrick received 2,419,582 Restricted Stock Units. Each RSU represents a contingent right to one share of PLUS Therapeutics common stock. These RSUs vest ratably in twelve equal quarterly installments beginning April 1, 2026, continuing each quarter until fully vested.

What are the vesting terms for the PSTV CEO’s RSU grant?

The RSUs vest ratably over twelve quarters. PLUS Therapeutics disclosed that 1/12th of the 2,419,582 RSUs vests on April 1, 2026, with the remaining RSUs vesting in substantially equal 1/12th increments on subsequent quarterly dates until all units are vested.

What stock options were granted to the PLUS Therapeutics CEO in this filing?

Marc H. Hedrick was granted 2,419,582 stock options, described as a Stock Option (Right to Buy). These options were awarded at a stated price of $0.0000 per option share in the filing and are subject to a four-year vesting schedule and change-of-control provisions.

How do the PSTV CEO’s stock options vest over time?

The options vest over four years in substantially equal 1/48th increments. PLUS Therapeutics states vesting occurs on each monthly anniversary of the grant date, with additional vesting acceleration upon a change of control in accordance with the CEO’s employment agreement.

Did the PLUS Therapeutics CEO buy or sell PSTV shares on the market?

The Form 4 reflects equity awards, not market purchases or sales. It reports grants of Restricted Stock Units and stock options to the CEO as compensation, with vesting over time, rather than an open-market buy or sell transaction in PLUS Therapeutics common stock.